IMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS:
|
|
- Thomasina George
- 5 years ago
- Views:
Transcription
1 Article DOI: /v y MB IMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS: А RETROSPECTIVE case-control STUDY V. Tzankova 1, V. Petrov 2 and N. Danchev 1 1 Medical University, Faculty of Pharmacy, Department of Pharmacology, Pharmacotherapy and Toxicology, Sofia, Bulgaria 2 National Heart Hospital, Sofia, Bulgaria Correspondence to: Virginia Tzankova virginia_tzankova@abv.bg ABSTRACT The scientific debate on oral contraceptives (OCs) therapy and thrombotic diseases continues unabated. This retrospective casecontrol study was intended to evaluate the age specific effects of oral contraceptives and smoking on the risk of deep venous, pulmonary thromboembolism and arterial thombosis in women under 50 years. The study included evaluation of registry records of Bulgarian women discharged from the National Heart Hospital, Sofia from 2005 through 2009 after thromboembolic event. The relative risk of thrombotic disease was seen to increase with oral contraceptive use. The risk of arterial disease OR 3.6 (CI ) exceeded those of venous disease OR 2.3 (CI ). In the data the relative risk of thrombotic diseases was seen to increase age-dependently. The increase was exponential for arterial, and linear for venous thromboembolism. The combination of smoking with oral contraceptives, containing low-dose ethinylestradiol (0.03 mg) and progestins may have synergistic effects on risks of arterial thromboembolism, and might aggravate venous. Most probably different factors that favor vascular narrowing or occlusion might explain the association between deep venous, pulmonary thromboembolism, OCs use and smoking. Women, especially older than 35 years, should be assessed for thrombogenic risk factors including smoking, hypertension, methabolic syndrome, and other vascular diseases prior to oral contraceptive use. Biotechnol. & Biotechnol. Eq. 2010, 24(3), Keywords: oral contraceptives, venous thromboembolism, arterial disease, smoking Introduction Oral contraceptives (OCs) are widely utilized method to prevent ovulation, implantation and therefore pregnancy. The high estrogen content (0.05 mg ethinyl estradiol) was though to be the main reason for increased risk of. This subsequently led to the development of new oral contraceptives with lower estrogen content (0.03 mg ethinylestradiol). They were considered safer, but recent studies have challenged the concept that reducing the dose of estrogen in oral contraceptives eliminates the risk of (23). In the last decade several new synthetic progestins were introduced in combined oral contraceptive preparations. Dienogest (hybrid progestin closed to the pregnane group) and drospirenon (derived from spironolactone) are new generation progestins with good ovulation inhibition, cycle control, tolerability and safety profile (12). They have significant antiandrogenic activity. It is still debated whether this property has resulted in lower risk in arterial or venous thromboembolism (20). Thrombosis caused by OCs can be venous or arterial; in the pulmonary, systemic or spanchnic circulation. Arterial is mainly associated with heightened platelet reactivity and damage to the vessel wall, although venous has been traditionally associated with blood stasis and hypercoagulability. Accordingly, classic risk factors for arterial and venous are usually considered distinct. Risk factors of arterial include smoking, hypertension, diabetes, the metabolic syndrome, and hyperlipidemia. However, a number of studies have recently challenged this dichotomy. It is now recognized that venous and arterial thromboses share several risk factors, suggesting a closer link between the two clinical conditions (1, 4, 9, 13, 17). Although the use of oral contraceptives might contribute to the development of, it would appear that smoking can independently increase the risk of thromboembolism (10). The morbidity and mortality of venous thromboembolism and arterial in Bulgaria is substantial. Deep venous (DVT) accounts for a great part of hospitalizations in the vascular surgery clinics in Bulgaria. The most serious complication of DVT is pulmonary embolism (PE). We therefore evaluated the age specific incidence of deep venous, pulmonary thromboembolism and arterial, and the recent impact of hormone therapy (combined low-dose oral contraceptives, containing estrogen component with new generation progestins) and smoking habits on these pathologies in Bulgarian women under the age of 50 years Biotechnol. & Biotechnol. Eq. 24/2010/3
2 Materials and Methods A case- control study of venous was conducted in National Heart Hospital in Sofia. The study included evaluation of registry records of Bulgarian woman discharged from the hospital from January 2005 until December 2009 after a thromboembolic event. Patients were interviewed about demographic characteristics, personal habits (including smoking and alcohol consumption) and history of medication. Diagnoses at discharge were later obtained from the hospital records. We confined our analyses to patients who were women years of age receiving OCs. The patients reported the use of low dose contraceptives (estrogen content of 0.03 mg ethinylestradiol) combined with progestin component dienogest (2 mg) or drospirenon (3 mg). We further excluded patients with diabetes mellitus, obesity, acute myocardial infarction, lipid abnormalities, varicose veins or pulmonary disease other than thromboembolic - all conditions which might predispose to the development of thromboembolism. Patients whose thromboembolism was secondary to trauma or surgical procedures were also excluded. Cases were women with diagnosis of a DVT or arterial admitted to the vascular surgery clinic of the participating hospital. A total of 65 cases of DVT and 43 cases with arterial at age 20 to 50 years (mean age 33) were included in the study. Controls were women admitted to the same hospital during the same period, for diseases other than VTE or arterial, and not related to known potential risk factors. There were 76 control women for DVT group and 51 controls for arterial groups. The women in the control group were comparable with the study cases in terms of age. Patients were matched for age within a five year tolerance. Standard methods of analysis, based on unconditional logistic regression, were used to derive odds ratios (OR), and the corresponding 95% confidence intervals (CI) (2). Results and Discussion Impact of oral contraceptives on development of DVT and arterial Table 1 presents distribution of DVT according to the hormone therapy (OCs). Seventeen patients with DVT (26.20%) reported the use of OCs. The risk for developing DVT increases after hormonal therapy. The OR was 2.3 compared to the group of non users. Within the hormone treated group, a total of 7.63% of the cases with DVT versus 4.61% of controls were current users of hormonal treatment and 18.46% versus 10.79% were past users. The risk of DVT decreases as the time since last hormonal use increases, although it still remained high. Table 2 presents distribution of arterial according to the hormone therapy. Nineteen patient with arterial (44.2%) had received OCs. Hormonal therapy increases the risk of arterial. The OR was 3.6 compared to the group of non users. The risk of arterial Biotechnol. & Biotechnol. Eq. 24/2010/3 decreases as the time since last hormonal use increases. Effect of smoking on thromboembolic events Out of the patients with DVT 41.5% were non-smokers compared with 43.1% of smokers (Table 3). In 15.4% of the cases with DVT a complication of PE occurred. With reference to the effect of smoking compared with non smokers, the OR of pulmonary embolism was 1.4 (95 CI ). PE occurred more often when smoking was combined with hormonal therapy (66.11% in patients with hormonal therapy vs. 33.9% in patients without hormonal therapy). Thus no clear evidence of a relation between venous thromboembolism and smoking habits was observed, while pulmonary embolisms were more often in smokers, who used therapy with hormones. In the group with arterial the smokers were 53.5% vs. 46.5% of non smokers. With reference to the effect of smoking compared with non smokers, the OR of arterial in smokers was 2.7 (95 CI ). Age specific incidence of deep venous and arterial Venous thromboembolic events incidence (femoropopliteal, iliofemoral venous and arterial ) among smoking women was modelled from the smoothed age specific incidence rates. Patients were matched for age within five year tolerance. Incidence of femoropopliteal venous among all women increased with age. It rose from 9.8% at age years to 28.5% at age years. Similar effects were observed in cases of iliofemoral venous. In this patient group the incidence rose from 7.1% at age years, to 38% at age over 45 years (Fig. 1). The smoking habits increased significantly the risk of developing arterial thromboembolic events with the age. It sharply increased from approximately 5% at age years to almost 73% at age of years. Patients (%) Age (years) Femoropopliteal venous Ilio-femoral venous Arterial Fig. 1. Age specific incidence of femoropopliteal, iliofemoral and arterial in smoking women under 50 years of age There is consistent evidence that the use of oral contraceptives is associated with increased risk of venous and arterial. A significant disability is more frequent in women suffering and surviving an arterial complication than 2027
3 Table 1 Distribution of 65 cases of deep venous (DVT) and 76 controls and odd ratios (with 95 confidence intervals, CI) according to OCs use in the period DVT Controls Odd ratios (OR, 95% CI) Hormone use (OCs) Patients (number) % Patients (number) % Never user * Ever user (CI ) *Reference category Table 2 Distribution of 43 cases of arterial and 51 controls and odd ratios (with 95 confidence intervals, CI) according to the hormonal therapy (OCs) in the period Arterial Controls Odd ratios (OR, 95% CI) Hormone use (OCs) Patients (number) % Patients (number) % Never user * Ever user (CI ) *Reference category Relation between smoking habits and deep venous thromboembolism with pulmonary embolism Table 3 Patients with femoropopliteal and iliofemoral venous Patients with thromboembolism complicated with pulmonary thromboembolism Odd ratios (95% CI) number % number % Non smokers* ** Smokers ( ) *Including former smokers who had currently abstained for over one year. **Reference category in women with venous thromboembolism. There is strong synergism between the use of OCs and other recognized risk factors such as tobacco smoking (15). This study assesses the effects of oral contraceptives and cigarette smoking on incidence of venous and arterial thromboembolic disease among women at age years. The patients reported the use of combined hormone preparations with low-estrogen (0.03 mg) and progestin component (dienogest or drospirenone). Although in the past the lower estrogen contraceptives combined with progestin component were considered to be relatively safe, recent studies have challenged that concept. Several studies suggested that certain progestins may increase the risk of associated with low-estrogen preparations (11, 24). Whereas the beneficial effects of new generation progestins (desogestrel, gestogen) on the level of high density lipoprotein cholesterol suggested that they might lower the risk of arterial, studies demonstrated that the relative risk of venous in users of these oral contraceptives was much higher than the risk of second generation progestins (levonorgestrel, norgestrel) (21). Results from the study showed that the risk of among hormone users was higher than in non users. The relative risk of confirmed arterial associated with OCs was 3.6 (CI ); the risk of venous was lower: OR 2.3 (CI ). The results confirm the existence of an increased risk associated with the use of modern oral contraceptives. The most serious adverse events of combined estrogen and progestin preparations are related to distribution along major vascular trunks (celiac, superior and inferior mesenteric) to the side of thrombus in either the arterial or venous system. Several pathophysiologic mechanisms have been proposed to explain the relationship between oral contraceptive use and hypercoagulable state: estrogen increase the procoagulant factors like prothrombin, factor VII, X, XII and XIII; estrogens have an effect on anticoagulant pathway by causing resistance to activated protein C; estrogens increase fibrinolysis; progestin exacerbate the effects of estrogens on procoagulant, anticoagulant and fibrinolytic pathways (7, 8, 22). Smoking is an important risk factor for cardiovascular diseases. Since there were considerable differences in the 2028 Biotechnol. & Biotechnol. Eq. 24/2010/3
4 smoking habits of patients in different age groups, we took this factor into account by a matching procedure. No clear evidence of relation between venous thrombotic events and smoking habits in non OCs users were observed. Nevertheless, the risk of complications, like pulmonary thromboembolism, substantially increased in smoking women who used OCs. It suggested an action of both risk factors on similar aspects of the pathogenic process (5, 8). Some evidence implicates smoking directly in the pathogenesis of thromboembolic states in the less platelet-dependent venous side of circulation (6, 14). Potential procoagulant mechanisms that might be associated with smoking are: increased fibrinogen level from increased interleukin-6, increased catecholamine release, increased tissue factor level, impaired fibrinolysis, impaired platelet activation (3, 6, 18). The above mechanisms are interrelated, and it is difficult to determine which abnormalities clearly result from smoking and also clinically increase the risk for VTE. We found a clear association between smoking habits with the risk of arterial. This may be related to the dose-dependent and reversible association of smoking with activation of coagulation and inflammation (25). Smoking has a direct effect on arterial walls, which range from endothelial dysfunction to atherosclerosis. We further analyzed the age specific incidence of DVT and arterial among smoking women at the age years. There was an exponential increase in risk of arterial thrombotic disease with age. We found that the relative effect of smoking on arterial became significant when combined with OCs in women older than 40 years. Possible mechanisms might include cumulative effects of risk factors on the arterial wall, decreased regular exercise increasing immobility that results in venous stasis and increasing systemic activation of blood coagulation (19). Smoking is an additional risk factor. In combination with OCs smoking aggravates the stage of arterial disease, especially in higher age (16). This multifactor set of conditions that favour vascular narrowing or occlusion seem to be the explanation for the association between DVT, PE, oral contraceptives and smoking. In conclusion, women older than 35 years should be assessed for thrombogenic risk factors including smoking, hypertension, methabolic syndrome, and other vascular diseases prior to oral contraceptive use. Further long-term vascular follow-up, especially of women at the age years, with regard to prior hormone therapy is needed. Conclusions Both non-clinical and clinical studies suggest a possible link of oral contraceptives to abnormalities in coagulation and fibrinolysis. The emphasis of researches connecting smoking to various aspects of coagulation and fibrinolysis has tended to focus primarily on the potential impact on atherosclerosis and do not deal with deep venous and arterial. This retrospective case-control study was performed to evaluate the age-specific effects of both oral contraceptives and smoking on the risk of deep venous Biotechnol. & Biotechnol. Eq. 24/2010/3 and arterial in women under 50 years of age. We found that the use of low dose oral contraceptives is associated with higher risk of both arterial and venous. The effect was more evident in women over 35 years. We found clear evidence that smoking increases the risk of arterial and that this effect was age-dependent. The incidence of deep venous was also higher in oral contraceptive users compared to non-users. The present study will allow a decision-based analyses and rational contraceptive use to individual woman taking into consideration their age and smoking habits. REFERENCES 1. Anderson F.A.Jr, Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., Forcier A., Dalen J.E. (1991) Arch. Intern. Med., 151, Breslow N.E. and Day N.E. (1980) In: Statistical methods in cancer research, IARC Science Publications, Lyon, p Chao F.C., Tullis J.L.,Alper C.A., Glynn R.J., Silbert J.E. (1982) Thromb. Haemost., 47, Cushman M., Kuller L.H., Prentice R. (2004) JAMA, 292, Davis M.C. (1999) Health Psychol., 18, Eliasson M., Asplund K., Evrin P.E., Lundblad D. (1995) Atherosclerosis, 113, Famodu A.A., Ehigiegba A.E., Fakoya T.A., Adeyi J., Diejomach F.M. (1991) Haematologia, 24, Fruzzetti F., Ricci C., Fioretti P. (1994) Contraception, 49, Goldhaber S.Z., Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Speizer F.E., Willett W.C., Hennekens C.H. (1997) JAMA, 277, Goldhaber S.Z. and Tapson V.F. (2004) Am. J. Cardiol., 93, Hannaford P.C. and Owen-Smith V. (1998) BMJ, 316, Henzl M.R and Edwards J.A. (2000) In: Progestins and antiprogestins in clinical practice, Marcel Dekker, New York, p Heit J.A., Melton L.J.III, Lohse C.M., Petterson T.M., Silverstein M.D., Mohr D.N, O Fallon W.M. (2001) Mayo Clin. Proc., 76, Hunter K.A., Garlick P.J., Broom I., Anderson S.E., McNurlan M. (2001) Clin. Sci., 100, Lidegaard O. (1999) Am. J. Obstet. Gynecol., 180, Lowe G.D.O. (2006) Journal of Thrombosis and Haemostasis, 4, Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. (1996) Am. J. Epidemiol., 143,
5 18. Mennen L.I., Balkau B., Charles M.A., D Hour A., le Mauff J.M. (1999) Thromb. Haemost., 82, Rumley A., Emberson J.R., Wannamethee S.G., Lennon L., Whincup P.H., Lowe G.D. (2006) Journal of Thrombosis and Haemostasis, 4, Sitruk-Ware R. (2002) Menopause, 9, Sitruk-Ware R. (2004) Maturitas, 47, Vandenbroucke J.P., Rosing K.W., Bloemenkamp M. (2001) The New England Journal of Medicine, 344, Winkler U.H. (1998) Contraception, 57, WHO Collaborative study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Lancet, 346, Wannamethee S.G., Lowe G.D.O., Shaper A.G., Rumley A., Lennon L., Whincup P.H. (2005) European Heart Journal., 26, Biotechnol. & Biotechnol. Eq. 24/2010/3
Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationTabac et Maladie Veineuse Thrombo-Embolique. Antoine ELIAS Hôpital Sainte Musse Toulon Novembre 2018
Tabac et Maladie Veineuse Thrombo-Embolique Antoine ELIAS Hôpital Sainte Musse Toulon Novembre 2018 Tabac: Facteur de risque de MTEV? Tabac - Thrombose Veineuse Association? Force de l association? Association
More informationRisk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare
Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare New data A paper published in May 2012 in the British Medical Journal
More informationContraccezione e tromboembolismo venoso
Contraccezione e tromboembolismo venoso Ida Martinelli Centro Emofilia e Trombosi Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico - Milano XXVII Congresso Nazionale FCSA Milano, 20-22.10.2016
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationAnnals of RSCB Vol. XVII, Issue 1/2012
CORRELATIONS BETWEEN ENDOTHELIAL DYSFUNCTION AND GLYCEMIA IN VENOUS THROMBOSIS PATHOGENESIS Codruţa Bădescu 1, Oana Bădulescu 2, Manuela Ciocoiu 2, Magda Bădescu 2, M. Costuleanu 2 1 DEPARTMENT OF INTERNAL
More informationAssessment of Fibrinogen Level in Sudanese Women Receiving Oral Contraceptive
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 3/ June 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Assessment of Fibrinogen Level in Sudanese Women Receiving Oral
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationCombined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases
Combined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Web appendix:
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationThe Epidemiology of Venous Thromboembolism
The Epidemiology of Venous Thromboembolism Richard H. White, MD Abstract Venous thromboembolism (VTE) occurs for the first time in 100 persons per 100,000 each year in the United States, and rises exponentially
More informationCatheter-Related Thrombosis A Catalyst of Complications
Catheter-Related Thrombosis A Catalyst of Complications Catheter-Related Occlusions 1,2 Most common non-infectious complication in the long-term use of CVCs, and in particular PICCs Approximately 1 in
More informationOral contraceptives Epidemiological aspects Øjvind Lidegaard
Oral contraceptives Epidemiological aspects Øjvind Lidegaard Professor Gynaecological Clinic 4232 Rigshospitalet Copenhagen University OC: Epidemiological aspects OC use OC and thrombosis - venous thromboembolism
More informationCURRENT HORMONAL CONTRACEPTION - LIMITATIONS
CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationThe risk of venous thromboembolism is markedly elevated in patients with diabetes
Diabetologia (2005) 48: 1017 1021 DOI 10.1007/s00125-005-1715-5 ARTICLE V. Petrauskiene. M. Falk. I. Waernbaum. M. Norberg. J. W. Eriksson The risk of venous thromboembolism is markedly elevated in patients
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationHormonal contraception and risk of venous thromboembolism: national follow-up study
Hormonal contraception and risk of venous thromboembolism: national follow-up study Øjvind Lidegaard, professor, 1 Ellen Løkkegaard, consultant, 2 Anne Louise Svendsen, statistician, 3 Carsten Agger, data
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationSession Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD
Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous
More informationAppendix A Materials Considered by Dr. Shelley Tischkau In addition to the materials specifically referenced in my report, the other materials I have considered are: Literature Editorial: Sex Hormone Binding
More informationEarly release, published at on November 7, Subject to revision.
CMAJ Early release, published at www.cmaj.ca on November 7, 2011. Subject to revision. Research Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based
More informationRESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United
More informationChapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy
Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer
More informationTaking it to Heart: Cases in Heart Disease. In this article: By Andrew MacDiarmid, MD, FRCPC. Case 1. Case 2
Focus on CME at the University of Manitoba Taking it to Heart: Cases in Heart Disease By Andrew MacDiarmid, MD, FRCPC Case 1 On a routine followup visit for hypertension, Mrs. A, 70, mentions she has recently
More information1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis
1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet
More informationORIGINAL INVESTIGATION. An Epidemiologic Study of Risk Factors for Deep Vein Thrombosis in Medical Outpatients
An Epidemiologic Study of Risk Factors for Deep Vein Thrombosis in Medical Outpatients The Sirius Study ORIGINAL INVESTIGATION Meyer-Michel Samama, MD(BiolPharm); for the Sirius Study Group Background:
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationVI.2. ELEMENTS FOR A PUBLIC SUMMARY
VI.2. ELEMENTS FOR A PUBLIC SUMMARY VI.2.1 Overview of Disease Epidemiology COCs (Combined Oral Contraceptives) containing DRSP-EE (Drospirenone- Ethinylestradiol) are indicated for the prevention of pregnancy
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationThrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor
Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service
More informationOral contraception in Denmark
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Oral contraception in Denmark 1998 2010 NADIA M. WILSON 1, MAJA LAURSEN 2 & ØJVIND LIDEGAARD 1 1 Gynecological Clinic, Rigshospitalet University
More informationPRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017
PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Gretchen E. Tietjen, MD Department of Neurology University of Toledo Disclosures Advisory Boards: Eli Lilly, Dr. Reddy s Common Stock: J&J,
More informationDianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication
Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication Dear Healthcare Professional, In agreement with the European Medicines
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationIDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES
IDEAL MANAGEMENT OF PULMONARY EMBOLISM Samuel Z. Goldhaber, MD Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine
More informationDoes low dose contraceptive pills increase stroke rate? A cross sectional study in North-West Iran
Original Article Does low dose contraceptive pills increase stroke rate? A cross sectional study in North-West Iran Mehdi Farhoudi 1, Ehsan Sharifipour 2, Hormoz Ayromlou 3, Saeed Charsouei 4, Elyar Sadeghihokmabadi
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationVenous Thrombo-Embolism (VTE)
Venous Thrombo-Embolism (VTE) Information for service users and carers RDaSH leading the way with care Older People s Mental Health Services Reducing risk of unwanted blood clots whilst in hospital About
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationIs thromboprophylaxis effective in reducing the pulmonary thromboembolism?
Is thromboprophylaxis effective in reducing the pulmonary thromboembolism? Fereshteh Rajabi (1), Masoumeh Sadeghi (2), Fereshteh Karbasian (3), Ali Torkan (4) Abstract BACKGROUND: Deep vein thrombosis
More informationPathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University
Pathology of pulmonary vascular disease Dr.Ashraf Abdelfatah Deyab Assistant Professor of Pathology Faculty of Medicine Almajma ah University Pulmonary vascular disease Type of pulmonary circulation: Types
More informationTHROMBOEMBOLIC EVENTS AFTER IVC FILTER PLACEMENT IN TRAUMA PATIENTS. Lidie Lajoie, MD SUNY Downstate Department of Surgery December 20, 2012
THROMBOEMBOLIC EVENTS AFTER IVC FILTER PLACEMENT IN TRAUMA PATIENTS Lidie Lajoie, MD SUNY Downstate Department of Surgery December 20, 2012 Background Trauma Patients at High Risk for VTE Spain, D.A.,
More informationRisk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study
British Journal of Obstetrics and Gynaecology August 1998, Vol. 105, pp. 896896 Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study Jonathan
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationUse of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationA study of clinical profile of 50 patients deep venous thrombosis at general hospital
Research Article A study of clinical profile of 50 patients with deep venous thrombosis at general hospital Kasabe P S 1, Jaykar R D 2, Lakhpatre S B 3* 1 Assistant professor, 2 Associate professor, 3
More informationI t is established that regular light to moderate drinking is
32 CARDIOVASCULAR MEDICINE Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality S G Wannamethee, A G Shaper... See end of article for authors affiliations...
More informationJordan M. Garrison, MD FACS, FASMBS
Jordan M. Garrison, MD FACS, FASMBS Peripheral Arterial Disease (PAD) Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous reflux Disease Varicose Veins Chronic Venous Stasis Ulcer Disease
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationRISK OF ISCHEMIC STROKE ASSOCIATED WITH LOW-DOSE ORAL CONTRACEPTIVE USE: A META-ANALYSIS
RISK OF ISCHEMIC STROKE ASSOCIATED WITH LOW-DOSE ORAL CONTRACEPTIVE USE: A META-ANALYSIS Dae Hyun Kim, MD, MPH 1, Joachim Bleys, MD, MPH 2, Marlis Gonzalez-Fernandez, MD 3, Rebecca Gottesman, MD 4 and
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationModerate alcohol consumption is associated with decreased
Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with
More informationConcern about the potential increased risk of cardiovascular
Myocardial Infarction and Use of Low-Dose Oral Contraceptives A Pooled Analysis of 2 US Studies Stephen Sidney, MD, MPH; David S. Siscovick, MD, MPH; Diana B. Petitti, MD, MPH; Stephen M. Schwartz, PhD,
More informationThyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationPotpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy
Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationTrudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins
1 Women's Health 2015: The 23rd Annual Congress FRIDAY, April 17, 2015 Trudy Bush Lecture: Using Progestins in Clinical Practice Commercial Disclosure: I am a consultant on litigation relating to the Mirena
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationOriginal Article Correlation analysis between the risk factors and lethal thrombus formation after lower limb fractures
Int J Clin Exp Med 2016;9(6):9527-9532 www.ijcem.com /ISSN:1940-5901/IJCEM0017067 Original Article Correlation analysis between the risk factors and lethal thrombus formation after lower limb fractures
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationPrevalence of pulmonary embolism at autopsy among elderly patients in a Chinese general hospital
Journal of Geriatric Cardiology (2016) 13: 894 898 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Prevalence of pulmonary embolism at autopsy among elderly patients in a Chinese
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationHormonal contraception and thrombosis. An update
Hormonal contraception and thrombosis. An update Øjvind Lidegaard Clinical Professor in Obstetrics & Gynaecology Barcelona, Spain, 21.2.2015 Department of Gynaecology, Rigshospitalet Faculty of Health
More informationAcute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI
Acute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose: CVR Global
More informationThrombotic Stroke and Myocardial Infarction with Hormonal Contraception
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception Øjvind Lidegaard, Dr. Med. Sci., Ellen Løkkegaard, Ph.D.,
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationRisk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge
ORIGINAL CLINICAL INVESTIGATION Open Access Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge Li Wang 1, Nishan
More informationrisk factors for stroke and myocardial infarction in women alone is therefore needed to provide a complete population as a whole.
Br Heart J 1989;61:403-9 Risk factors for stroke and myocardial infarction in women in the United Kingdom as assessed in general practice: a case-control study S G THOMPSON,* G GREENBERG,t T W MEADE From
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationDVT and Pulmonary Embolus. Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre
DVT and Pulmonary Embolus Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre Overview Structure of deep and superficial venous system of upper
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form. Performance Measure Name: Venous Thromboembolism Prophylaxis
Last Updated: Version 4.3 NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Measure Set: Venous Thromboembolism (VTE) Set Measure Set I #: Performance Measure Name: Venous
More informationHORMONES AND COAGULATION. Victor Gerdes Internist Slotervaart Hospital and Academic Medical Center Amsterdam
HORMONES AND COAGULATION Victor Gerdes Internist Slotervaart Hospital and Academic Medical Center Amsterdam Overview Introduction Thyroid hormone Cortisol Prolactin Implications VTE Risk Factors Genetic:
More informationPrevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series.
Prevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series. Dr R King, Miss GE Jackson, Mr SR Platt Wirral University
More informationIncidence of Diagnosed Deep Vein Thrombosis in the General Population: Systematic Review
Eur J Vasc Endovasc Surg 25, 1±5 (2003) doi:10.1053/ejvs.2002.1778, available online at http://www.sciencedirect.com on REVIEW Incidence of Diagnosed Deep Vein Thrombosis in the General Population: Systematic
More informationVenous thromboembolism (VTE) is a common disease. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
Menopause: The Journal of The North American Menopause Society Vol. 18, No. 5, pp. 488/493 DOI: 10.1097/gme.0b013e3181f9f7c3 * 2011 by The North American Menopause Society Hormone therapy and recurrence
More informationORIGINAL INVESTIGATION. Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism A Population-Based Case-Control Study ORIGINAL INVESTIGATION John A. Heit, MD; Marc D. Silverstein, MD; David N. Mohr, MD; Tanya M. Petterson,
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationProper Diagnosis of Venous Thromboembolism (VTE)
Proper Diagnosis of Venous Thromboembolism (VTE) Whal Lee, M.D. Seoul National University Hospital Department of Radiology 2 nd EFORT Asia Symposium, 3 rd November 2010, Taipei DVT - Risk Factors Previous
More information